Heartburn Pill in Short Supply After Word of Covid-19 Trial - (Bloomberg via NewsPoints Desk)

  • The H2 blocker famotidine has been added to the FDA's list of drug shortages, just over a week after a report said it was being tested in high intravenous doses as a potential treatment for COVID-19 patients, reported Bloomberg.

  • Drugmakers including Teva, Carlsbad Technology and Aurobindo reported increased demand for the tablets, which are known in branded form as Pepcid.

  • Teva said several bottles were on backorder with expected recovery in the fourth quarter, while Aurobindo said availability to support incremental demand is estimated for the week of June 15.

  • Meanwhile, Carlsbad reported to the FDA that "we do have some stock, however, due to such high demand, we cannot send to all customers. We send as much as we can."

  • The journal Science recently reported on a clinical trial in which critically ill COVID-19 patients at Northwell Health in the New York City area were receiving nine times the heartburn dose.

  • Interim results from 391 patients could be known in "a few weeks," according to a hospital researcher.

To read more NewsPoints articles, click here.